You are certainly not alone if you struggle with watching (hopefully) a medical practitioner readying a needle for the introduction of clear liquid into your IV, or even directly in to your vein. Equally, or perhaps even more frightening, is that there exist many occasions when you will not be in possession of the faculties sufficient to observe the same administration and question what you are about to receive. Little things like comas and sleep. While you are probably not a doctor, there is something reassuring about being able to ask what you are to be injected with, if for no other reason than the inherent comfort in giving the needle wielder a moment to think.
Medisafe 1 Technologies (OTC: MFTH) knows how you feel. More importantly, it has developed a syringe locking system that requires both a database and barcode failsafe mechanism and also an override in order to physically function. Read: You won’t accidently be given 200ccs of insulin following a simple tonsillectomy.
The scope of these “accidental deliveries” by syringe is truly frightening. Just as Truman Capote’s “In Cold Blood” brought to light the absurdity and consequences of being rumored to keep valuables in the home, there are a numerous studies that make the hair on your neck stand straight up in the air when examined. The sheer movement of Medisafe’s stock, however, takes precedence.
Medisafe 1 Technologies gained $0.0027 in yesterday’s trading. While that number remains well below a single cent of movement, it accounted for a gain of an even 180%. You do the math. That was a staggering day of trading on a volume over 123 million shares changing hands. Numbers like these should never be looked at as less than nearly tripling your investment in a single day.
The stock traded steadily on the rise from yesterday’s opening bell. Closing the day at $0.0042 after opening at absolute zero, but finding its way to a low of $0.0015.
The aforementioned scary truths spoken of earlier? In a paper published online by Dr. Andreas Valentin in The British Medical Journal (2009) look at a few things he found in his 24-hour study of 113 ICU units in 27 countries:
“Valentin and his team found from their research was that, in a total of 1,328 patients, 861 errors affecting 441 patients were reported over the 24-hour period. Just over two thirds (67%) of patients experienced no error, 250 patients (19%) experienced only one error and 191 patients (14%) experienced more than one error. Although 71% of the errors resulted in no change in the status of the patient, 12 patients (0.9% of the total study population) suffered permanent harm or death related to a total of 15 medication errors that occurred at the administration stage. Trainees were reported as being involved in eight of these errors.
The most frequent mistakes related to wrong time of administration (386) and missed medication (259), followed by wrong dose (118), wrong drug (61), and wrong route (37). Workload / stress / fatigue was reported by ICU staff as a contributing factor in 32% of all errors. Other contributing factors included a recently changed drug name (18%), communication – written (14%), communication – oral (10%) and violation of standard protocol (9%).”
This is nothing short of staggering. Look to Medisafe to use the hundreds of similar reports available to make sure its stock continues to shoot for properly administered stars.